Milestones
1999
- Incorporated the company ‘Claris Lifesciences Limited’
2002
- Inaugurated the first manufacturing facility with 3 production lines for injectables products
2003
- Set up a new manufacturing facility, marking a new beginning for Hospital Care products
- Received INVIMA (Colombia) and ANVISA (Brasil) approvals for manufacturing facility
2004
- Commenced commercial production at infusion manufacturing facility
- Received ISO 9001 : 2000 certification
2005
- Received MHRA (UK) approval for injectables manufacturing facility
2006
- Investment by Carlyle Group of USD 20 million
2007
- Received US FDA approval for injectables manufacturing facility
- Received Gold Award in India Manufacturing Excellence Awards from Frost & Sullivan
2008
- Commenced own sales and marketing activities in the USA
- Received Gold Award in India Manufacturing Excellence Awards from Frost & Sullivan
2009
- Claris USA subsidiary entered into business arrangement with Pfizer Asia Contract Operations Pte. Ltd. For marketing and supply of specific sterile injectables in certain regulated markets
- Received Gold Award in India Manufacturing Excellence Awards from Frost & Sullivan
- Received Indian Drug Manufacturers' Association Quality Excellence Award
2010
- Debuted at Bombay Stock Exchange, and launched IPO
- Received Indian Drug Manufacturers' Association Quality Excellence Award
- Ranked #1 in ‘Healthcare’ and #37 among ‘India’s Best Companies To Work For’ by The Economic Times and Great Place to Work® Institute, India
2011
- Received a nod for marketing Propofol in European Union
- Ranked #1 in ‘Healthcare’ and #9 among ‘India’s Best Companies To Work For’ by The Economic Times and Great Place to Work® Institute, India
2012
- Ranked #1 in ‘Healthcare’ for third time in a row, and #13 among ‘Top 50 Companies Having 1,000+ Employees’ by The Economic Times and Great Place to Work® Institute, India
- Entered into a Joint Venture agreement with Japan-based companies Otsuka Pharmaceutical Factory, Inc. and Mitsui & Co. Ltd. for Infusion business in India and emerging markets, forming JV company ‘Claris Otsuka’
2013
- Commenced functions of JV company ‘Claris Otsuka’
- Ranked #1 in ‘Healthcare’ for the fourth time in a row, and #15 among ‘Top 100 Best Companies To Work For’ by The Economic Times and Great Place to Work® Institute, India
2014
- Inaugurated new injectables plant
- Received MHRA (UK) approval for new injectables plant
- Carved out a wholly-owned subsidiary, 'Claris Injectables Ltd.', with a view to bring focus on specialty injectables business
- Ranked #1 in ‘Healthcare’ for the fifth time in a row, and one of ‘India's Best Companies To Work For’ by The Economic Times and Great Place to Work® Institute, India
- Received Silver Award from MedAssets, USA
2015
- Launched Critical Care division for domestic market in a new avatar as ‘Claris Specialty Injectables’
- Received Gold Award from MedAssets, USA
- Ranked among the best in ‘Healthcare’, and one of ‘India's Best Companies To Work For’ by The Economic Times and Great Place to Work® Institute, India, for the sixth year in a row
2016
- Entered into a definitive agreement with Baxter International Inc., USA for sale of global generic injectables business for USD 625 million
- Ranked #1 once again in ‘Healthcare’ and among Top 50 in ‘India's Best Companies To Work For’ by The Economic Times and Great Place to Work® Institute, India
- Listed in Fortune India ‘The Next 500’
- Received Gold Award from MedAssets, USA
- Received Global HR Excellence Awards by World HRD Congress
- Received Great Manager Awards by People Business and The Times of India
- Recognised among India’s Top 50 Most Promising Brands by World Consulting and Research Corporation
2017
- Completed sale of global generic injectables business to Baxter International Inc., USA
- Ranked one of the best companies in ‘Healthcare’ and one of ‘India's Best Companies To Work For’ by The Economic Times and Great Place to Work® Institute, India, for the eighth time
- Declared as a ‘Great Place to Work® Certified’ company by Great Place to Work® Institute, India
- Listed in Fortune India ‘The Next 500’
- Completed sale of stake in 'Claris Otsuka', and exited from the Joint Venture
2018
- Voluntarily de-listed equity shares of the company from the Bombay Stock Exchange
